Polyclonal Antibody to 2',3'-Cyclic Nucleotide 3'-Phosphodiesterase (CNP)
| Code | Size | Price |
|---|
| PAC269Mu01-20ul | 20ul | £88.00 |
Quantity:
| PAC269Mu01-100ul | 100ul | £165.00 |
Quantity:
| PAC269Mu01-200ul | 200ul | £223.00 |
Quantity:
| PAC269Mu01-1ml | 1ml | £512.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Mouse
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
2,3CNP; 2,3-CNP; CNPCNP1; Cyclic-CMP Phosphodiesterase; 2',3'-Cyclic AMP Phosphodiesterase; CNPase; 2':3'-CNMP-3'-ase
Buffer Formulation:
PBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
Item Name:
2',3'-Cyclic Nucleotide 3'-Phosphodiesterase
Reactivity:
Hu;Ra;
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 0.2-2ug/mL;1:250-2500
Immunohistochemistry: 5-20ug/mL;1:25-100
Immunocytochemistry: 5-20ug/mL;1:25-100
Optimal working dilutions must be determined by end user.
Immunohistochemistry: 5-20ug/mL;1:25-100
Immunocytochemistry: 5-20ug/mL;1:25-100
Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant 2',3'-Cyclic Nucleotide 3'-Phosphodiesterase (CNP) | RPC269Mu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||